The cytokine IL-21 was proposed as a suitable target for an immuno-modulatory strategy, and glucagon-like peptide-1 receptor agonists were reported to be appropriate for β-cell protection in the context of T1D. Here, GLP1R is linked to type 1 diabetes mellitus.